SIGNIFICANCE STATEMENT
Distal renal tubular acidosis (dRTA) is defined by the inability of the distal nephron to acidify the urine and can be associated with sensorineural deafness. About a third of patients with inherited dRTA have no identified causative mutations in known disease genes. Here we report recessive mutations in the forkhead transcription factor FOXI1 as a novel cause of dRTA with deafness. Our findings enable a precise diagnosis in affected patients, inform genetic counselling, as well as cascade screening and provide insight into the transcriptional regulation of transport proteins in the distal nephron and inner ear by FOXI1.
INTRODUCTION
An important homeostatic function of the kidney is the regulation of acid-base balance. This occurs in the proximal tubule via bicarbonate reabsorption and in the collecting duct system via proton secretion. The intercalated cells of the collecting duct use specific transporters to regulate acid-base balance that can secrete protons (type A intercalated cells) and bicarbonate (type B intercalated cells). 1 Impaired type A intercalated cell function may lead to an inability to acidify the urine and secrete acids, with consequent development of hyperchloremic non-anion gap metabolic acidosis. Mutations known to cause inherited dRTA have been identified in transporters present in the type A intercalated cells and include the B1 and a4 subunits of the vacuolar H + -ATPase (V-ATPase), anion exchanger 1 (AE1) and the cytosolic carbonic anhydrase (CAII). [2] [3] [4] Interestingly, mutations in the V-ATPase B1 subunit are typically associated with sensorineural deafness, as can be those in a4, 2, 5 emphasizing functional similarities between the epithelium of the inner ear and that of the collecting ducts of the kidney. 6 This is due to the expression of a common set of membrane transport proteins in distinct cell types of the epithelium of the inner ear and the renal collecting duct.
Specifically, Forkhead related (FORE) cells of endolymphatic duct and sac epithelium of inner ear 7 and intercalated cells express B1 and a4 subunits of the V-ATPase proton pump and also the anion-exchange protein AE4 and pendrin. 7, 8 A genetic impairment of urine acidification can be associated with an altered pH/ionic composition in the inner ear fluid and hence prevent proper sound perception. Another common feature of these cell types is that they each express FOXI1 -a transcription factor that has been shown to be crucial for regulation of AE1, AE4, and the V-ATPase subunits B1, a4, A and E2. 8 Consistent with this, mice with a germline deletion of Foxi1 display sensorineural deafness and dRTA, 9, 10 together with reduced expression of these target genes. Although, a family has been identified, in which Pendred syndrome (PS) segregates with a composite heterozygous genotype of single allele mutations in SLC26A4 and FOXI1 (Yang et al.) , yet, recessive loss-of-function mutations in FOXI1 have not been described in human patients.
In this report, we describe two novel missense mutations that do not directly affect membrane transport proteins but rather hit cell function at the transcriptional regulatory level -in that they prevent the transcription factor FOXI1 from binding to regulatory DNA cis-elements of target gene promoters. This leads to a severely reduced activation of those target genes, including membrane transport proteins, which require FOXI1 interactions for proper expression. In this way, these two novel loss-of-function mutations induce a severe syndrome of deafness and acidosis with a phenotype very similar to that of mice that altogether lack Foxi1 expression.
RESULTS AND DISCUSSION

CASE REPORTS
Two consanguineous kindreds with an autosomal recessive pattern of distal renal tubular acidosis and sensorineural deafness were evaluated (Fig. 1) . In family 1, the male proband (Patient 1.1) was the eldest of 3 children, with one affected sister (Patient 1.2; Fig. 1A ). In family 2, the female proband (Patient 2.1) was the only affected family member (Fig. 1B) .
Key clinical features in all affected patients included early onset sensorineural hearing loss requiring cochlear implants, a hypokalemic, hyperchloremic metabolic acidosis at presentation with inappropriately high urine pH, failure-to-thrive, and bilateral nephrocalcinosis (Fig 1E) , consistent with dRTA. The deafness was profound and was associated with dilatation of the vestibular aqueduct ( Fig. 1F and S3-4). The dRTA was associated with hypercalciuria and nephrocalcinosis noted at presentation, but responded to treatment with both alkali and potassium supplements with subsequent catch-up in growth of the children. In addition, patients 1.1 and 2.1 also developed medullary cystic changes within the kidney ( Fig. 1E and 1F ). Clinical data are summarized in Table 1 .
STRUCTURAL ANALYSIS OF MUTATED FOXI1 PROTEINS
The novel FOXI1 homozygous missense mutations, p.L146F and p.R213P, were identified following whole exome sequencing in the affected patients, with segregation of the alleles from the parents ( Fig. 1C and 1D ). The mutations were not found in the EXaC database. Both missense changes were located within evolutionary highly conserved residues of the FOXI1 protein (Fig. 1G) . Consistent with FOX protein sequence alignments ( Fig. 1G and Fig. S1 ), in silico modelling of FOXI1, using the crystal structure of rat Foxa3, 11 predicted that FOXI1 L146 occupies a homologous position to L142 in α-helix 2 (α2) of the Foxa3 DNA-binding domain ( Fig. 1H and 1I) . A stabilizing interaction between Foxa3 and its cognate DNA is formed between the side-chain δ1 carbon atom of L142 and the ribose DNA backbone.
11
Identical results were obtained when modelling FOXI1 on the structures of human FOXM1, 12 human FOXO4, 13 human FOXK2, 14 and rat Foxd3 15 ( Fig. S2) , with similar protein-DNA interactions identified for the homologous leucine residues in these structures. The FOXI1 L146F mutation was predicted to disrupt this stabilizing protein-DNA interaction, with the larger (~30Å 3 ), 16 rigid aromatic ring of phenylalanine predicted to impinge upon the ability of the recognition helix (α3) to fully engage the major groove of the target DNA (Fig. 1J ). The functional importance of a small hydrophobic residue at this position in the DNA binding domain is highlighted by the almost complete conservation of a leucine residue in the FOX protein family (Fig. S1 ). FOXI1 R213 was predicted to occupy a homologous position to L209 in the wing 2 domain of Foxa3 (Fig. 1K ). Similar to Foxa3 L142, the side-chain β-carbon atom of Foxa3 L209 interacts with the ribose DNA backbone. 11 Therefore, we hypothesized that FOXI1 R213 also served to stabilize the interaction with its target DNA, similar to the role of R210, R211 and R214 in Foxa3 (Fig. 1K) . Substitution of the positively charged side-chain of arginine with proline (p.R213P) will destroy the predicted electrostatic interaction with the DNA, thereby disrupting DNA binding (Fig. 1L) . (Further modeling information is detailed in the Supplementary Appendix).
FUNCTIONAL ANALYSIS OF MUTATED FOXI1 PROTEINS
We further investigated the functional effect of the mutations in vitro. First, we assessed protein expression levels of transfected wild type and the mutations p. L146F and p.R213P of FOXI1 in the human kidney cell line HEK 293T, which did not differ ( Fig. 2A) The patients in the present study did not show any signs of goiter, available data on thyroid function was normal. Furthermore, we demonstrate that patients with recessive loss-offunction mutation in FOXI1 display dRTA and deafness with EVA, suggesting that complete loss of FOXI1 activity induces a unique and distinct phenotype. In a previous report, Pendred syndrome associated with a digenic pattern of inheritance in which a composite heterozygous genotype with mutations in FOXI1 and SLC26A4 segregates with deafness and an EVA. 18 In this patient goiter was not noted and the contributing missense mutation in FOXI1 was located approximately 50 amino acids C-terminally of the DNA-binding domain.
Also in this report, the authors identify five patients with PS and non-syndromic EVA with a single mutation in one of the FOXI1 alleles and they speculate that perhaps also single mutations can cause PS and non-syndromic EVA. The apparent lack of a clinical phenotype in the parents of our patients indicates that isolated heterozygous loss of function of FOXI1
does not cause disease, consistent with observations in mice with a heterozygous germ line deletion of Foxi1, who also have no phenotype. 7,9 A similar conclusion was reached in patients with EVA and heterozygous variants in FOXI1, as none had a family history of deafness. 18 Based on this, we find it unlikely that a single mutation in one FOXI1 allele will cause disease. However, in combination with another single allele mutation -for instance in a gene that regulate SLC26A4 -a single allele mutation in FOXI1 could be part of the pathogenetic mechanism underlying PS with non-syndromic EVA.
Of interest, in mice lacking Foxi1, males have been shown to be infertile. 19 This is due to a failure of clear cells in the epididymis to acidify the extracellular luminal fluid. This leads to a pathological post-testicular sperm maturation and, as a consequence, spermatozoa from
Foxi1 null males fail to reach the female genital tract in sufficient number to allow fertilization. 19 Whether mutations in FOXI1 will be associated with reduced male fertility also All three patients in this study were noted to have medullary renal cysts, raising the question whether FOXI1 could also be involved in cystogenesis. Yet, an association of dRTA with cysts is well recognized: in our own cohort of children with dRTA, over a third developed cysts during childhood. 20 Typically, this is ascribed to hypokalemia, 21 although other factors, such as hypercalciuria/nephrocalcinosis have also been implicated. 22 Observations in more patients with dRTA are needed to better assess the frequency of cysts in FOXI1-based dRTA compared to other genetic forms.
Approximately a third of patients with dRTA have no identified causative mutation in recognized disease genes, 20, 23, 24 and thus should be tested for FOXI1 mutations to help establish a precise diagnosis with consequent genetic counseling -especially in cases involving hearing and possibly also male fertility problems. Parents provided written informed consent. Three subjects with dRTA and sensorineural deafness, without identified mutations in known disease genes were investigated. We performed whole exome sequencing using peripheral blood DNA from affected family members. Sanger sequencing was used to validate the variants identified by whole exome sequencing in both affected children. In silico modelling and biochemical analysis was performed with human FOXI1 protein as a control compared with the two mutated FOXI1
proteins. 
SNP detection
The base quality of each sequence read was inspected for low quality calls and subsequently removed before proceeding with further processing. Using a sliding window approach, bases with low quality were removed from the 3' and 5' ends. Bases were removed if the average quality was below the threshold of 15. Finally, only reads with both forward, and reverse read, were used for the next analysis step. Mapping to the reference database (hg19, NCBI37) was performed using Burrows-Wheeler Alignment (BWA) method with default parameters. The SNP and Indel calling was performed using GATK's UnifiedGenotyper using a Bayesian genotype likelihood model to estimate simultaneously the most likely genotypes and allele frequency in a population of N samples. Variants detected were annotated based on their gene context using snpEff. The total reads were ~145M with the percentage of mapped reads 99%. Data was pipelined to allow Indel and SNP vcf files to be generated which were viewed using Ingenuity Variant Analysis software (Qiagen). 
Filtering criteria used for single nucleotide variants (SNVs), and insertion and deletion selection (Indel).
SUPPLEMENTARY APPENDIX
In silico modelling
The DNA-binding domain (residues 121-221) of human FOXI1 (accession number NP_036320) was modelled against the crystal structure of rat Foxa3 (hepatocyte nuclear factor-3γ/HNF-3γ)) (PDB accession code 1VTN) 1 using HHPred 2 and Modeller 3 software.
Homology model figures were prepared using PyMOL (http://www.pymol.org/). Consistent with protein sequence alignments (Fig. S1 ), identical results were obtained using the crystal structures of FOXM1, 4 FOXO4, 5 FOXK2, 6 and Foxd3 7 (Fig. S2 ). It should be noted that predicted position of the FOXI1 R213 residue was specific to the Foxa3 homology model since this region of the wing 2 domain in the other structures used for modelling was either not resolved or captured in contact with the DNA. Interestingly, a similar missense mutation (p.R169P) in FOXC1 has been shown to disrupt DNA binding and transcriptional activation. 8 Sequence analysis predicts FOXC1 R169 occupies a homologous position to FOXI1 R214, just one residue downstream of FOXI R213 (Fig. S1 ), thereby providing further evidence for the functional importance of this domain.
Plasmid constructs
Full length FOXI1 coding sequence was previously cloned into the expression vector pcDNA3.1. 9 FOXI1 was also cloned in-frame with GFP in the expression vector pEGFP-N3
(Clontech, USA), to make FOXI1-GFP fusion protein. Mutant FOXI1 L146F and R213P were generated by site-directed mutagenesis using Quikchange Lightning Site-directed mutagenesis kit (Agilent Technologies, USA) using the following primers (mutations underlined): Promoter reporter constructs were previously generated by cloning promoter regions of ATP6V0A4, 10 AE1 (SLC4A1), 9 and pendrin (SLC26A4) 9 into pGL3 Basic vector (Promega, USA).
The sequence of each construct was verified by Sanger sequencing performed by GATC Biotech Ltd (Germany). 
